FGFR2 and cholangiocarcinoma: Treatment of FGFR inhibitor-refractory cholangiocarcinoma represents an area of unmet need.19,24 It is notable that tinengotinib, as a multi-target tyrosine kinase inhibitor, demonstrated inhibitory activity against FGFR kinases in vitro3 as well as in patients harboring FGFR2 kinase domain (N549K) or transmembrane domain (C382R) mutations in the present study.